OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure
Lisa C. Costello-Boerrigter, William B. Smith, Guido Boerrigter, et al.
AJP Renal Physiology (2005) Vol. 290, Iss. 2, pp. F273-F278
Open Access | Times Cited: 253
Lisa C. Costello-Boerrigter, William B. Smith, Guido Boerrigter, et al.
AJP Renal Physiology (2005) Vol. 290, Iss. 2, pp. F273-F278
Open Access | Times Cited: 253
Showing 26-50 of 253 citing articles:
Chronic Administration of Oral Vasopressin Type 2 Receptor Antagonist Tolvaptan Exerts Both Myocardial and Renal Protective Effects in Rats With Hypertensive Heart Failure
Hanako Morooka, Yoshitaka Iwanaga, Yodo Tamaki, et al.
Circulation Heart Failure (2012) Vol. 5, Iss. 4, pp. 484-492
Open Access | Times Cited: 52
Hanako Morooka, Yoshitaka Iwanaga, Yodo Tamaki, et al.
Circulation Heart Failure (2012) Vol. 5, Iss. 4, pp. 484-492
Open Access | Times Cited: 52
Blood pressure-lowering efficacy of loop diuretics for primary hypertension
Vijaya M Musini, Pouria Rezapour, James M Wright, et al.
Cochrane library (2015) Vol. 2015, Iss. 5
Open Access | Times Cited: 48
Vijaya M Musini, Pouria Rezapour, James M Wright, et al.
Cochrane library (2015) Vol. 2015, Iss. 5
Open Access | Times Cited: 48
Hyponatremia in critical care patients: Frequency, outcome, characteristics, and treatment with the vasopressin V2-receptor antagonist tolvaptan
Bruce Friedman, Joshua Cirulli
Journal of Critical Care (2012) Vol. 28, Iss. 2, pp. 219.e1-219.e12
Closed Access | Times Cited: 48
Bruce Friedman, Joshua Cirulli
Journal of Critical Care (2012) Vol. 28, Iss. 2, pp. 219.e1-219.e12
Closed Access | Times Cited: 48
Acute heart failure volume control multicenter randomized (AVCMA) trial: Comparison of tolvaptan and carperitide
Satoshi Suzuki, Akiomi Yoshihisa, Takayoshi Yamaki, et al.
The Journal of Clinical Pharmacology (2013) Vol. 53, Iss. 12, pp. 1277-1285
Open Access | Times Cited: 46
Satoshi Suzuki, Akiomi Yoshihisa, Takayoshi Yamaki, et al.
The Journal of Clinical Pharmacology (2013) Vol. 53, Iss. 12, pp. 1277-1285
Open Access | Times Cited: 46
Tolvaptan Reduces the Risk of Worsening Renal Function in Patients With Acute Decompensated Heart Failure and Preserved Left Ventricular Ejection Fraction ― Prospective Randomized Controlled Study ―
Shunsuke Tamaki, Yoshihiro Sato, Takahisa Yamada, et al.
Circulation Journal (2017) Vol. 81, Iss. 5, pp. 740-747
Open Access | Times Cited: 46
Shunsuke Tamaki, Yoshihiro Sato, Takahisa Yamada, et al.
Circulation Journal (2017) Vol. 81, Iss. 5, pp. 740-747
Open Access | Times Cited: 46
Therapeutic Potential of Vasopressin-Receptor Antagonists in Heart Failure
Yasukatsu Izumi, Katsuyuki Miura, Hiroshi Iwao
Journal of Pharmacological Sciences (2014) Vol. 124, Iss. 1, pp. 1-6
Open Access | Times Cited: 45
Yasukatsu Izumi, Katsuyuki Miura, Hiroshi Iwao
Journal of Pharmacological Sciences (2014) Vol. 124, Iss. 1, pp. 1-6
Open Access | Times Cited: 45
Decongestive Therapy and Renal Function in Acute Heart Failure
Steven R. Goldsmith, Bradley A. Bart, John C. Burnett
Circulation Heart Failure (2014) Vol. 7, Iss. 3, pp. 531-535
Open Access | Times Cited: 45
Steven R. Goldsmith, Bradley A. Bart, John C. Burnett
Circulation Heart Failure (2014) Vol. 7, Iss. 3, pp. 531-535
Open Access | Times Cited: 45
Electrolyte imbalance and its determinants between low and high dose of furosemide in patients admitted to tertiary care hospital of Nepal: A prospective cohort study
Hari Khanal, Sandhya Sharma, Govinda Bhandari, et al.
Research Square (Research Square) (2025)
Closed Access
Hari Khanal, Sandhya Sharma, Govinda Bhandari, et al.
Research Square (Research Square) (2025)
Closed Access
Pharmacokinetic and Pharmacodynamic Interaction Between Tolvaptan, a Non-Peptide AVP Antagonist, and Furosemide or Hydrochlorothiazide
Susan E. Shoaf, Steven L. Bramer, Patricia Bricmont, et al.
Journal of Cardiovascular Pharmacology (2007) Vol. 50, Iss. 2, pp. 213-222
Open Access | Times Cited: 56
Susan E. Shoaf, Steven L. Bramer, Patricia Bricmont, et al.
Journal of Cardiovascular Pharmacology (2007) Vol. 50, Iss. 2, pp. 213-222
Open Access | Times Cited: 56
Effects of Oral Tolvaptan in Patients Hospitalized for Worsening Heart Failure: The EVEREST Outcome Trial
M.D. Cheitlin
Yearbook of Cardiology (2008) Vol. 2008, pp. 386-388
Closed Access | Times Cited: 56
M.D. Cheitlin
Yearbook of Cardiology (2008) Vol. 2008, pp. 386-388
Closed Access | Times Cited: 56
The Cardiorenal Syndrome: Making the Connection
Gautham Viswanathan, Scott F. Gilbert
International Journal of Nephrology (2010) Vol. 2011, pp. 1-10
Open Access | Times Cited: 48
Gautham Viswanathan, Scott F. Gilbert
International Journal of Nephrology (2010) Vol. 2011, pp. 1-10
Open Access | Times Cited: 48
Phase III Clinical Pharmacology Study of Tolvaptan
Takayuki Inomata, Tohru Izumi, Masunori Matsuzaki, et al.
Cardiovascular Drugs and Therapy (2011) Vol. 25, Iss. S1, pp. 57-65
Closed Access | Times Cited: 47
Takayuki Inomata, Tohru Izumi, Masunori Matsuzaki, et al.
Cardiovascular Drugs and Therapy (2011) Vol. 25, Iss. S1, pp. 57-65
Closed Access | Times Cited: 47
The Critical Link of Hypervolemia and Hyponatremia in Heart Failure and the Potential Role of Arginine Vasopressin Antagonists
Jalal K. Ghali, S. William Tam
Journal of Cardiac Failure (2010) Vol. 16, Iss. 5, pp. 419-431
Closed Access | Times Cited: 44
Jalal K. Ghali, S. William Tam
Journal of Cardiac Failure (2010) Vol. 16, Iss. 5, pp. 419-431
Closed Access | Times Cited: 44
Clinical benefit of tolvaptan in patients with acute decompensated heart failure and chronic kidney disease
Yusuke Uemura, Rei Shibata, Kenji Takemoto, et al.
Heart and Vessels (2015) Vol. 31, Iss. 10, pp. 1643-1649
Closed Access | Times Cited: 39
Yusuke Uemura, Rei Shibata, Kenji Takemoto, et al.
Heart and Vessels (2015) Vol. 31, Iss. 10, pp. 1643-1649
Closed Access | Times Cited: 39
Effectiveness and safety of tolvaptan in liver cirrhosis patients with edema: Interim results of post‐marketing surveillance of tolvaptan in liver cirrhosis (START study)
Isao Sakaida, Shuji Terai, Masayuki Kurosaki, et al.
Hepatology Research (2016) Vol. 47, Iss. 11, pp. 1137-1146
Closed Access | Times Cited: 38
Isao Sakaida, Shuji Terai, Masayuki Kurosaki, et al.
Hepatology Research (2016) Vol. 47, Iss. 11, pp. 1137-1146
Closed Access | Times Cited: 38
Prognostic Impact of Loop Diuretics in Patients With Chronic Heart Failure – Effects of Addition of Renin-Angiotensin-Aldosterone System Inhibitors and β-Blockers –
Masanobu Miura, Koichiro Sugimura, Yasuhiko Sakata, et al.
Circulation Journal (2016) Vol. 80, Iss. 6, pp. 1396-1403
Open Access | Times Cited: 35
Masanobu Miura, Koichiro Sugimura, Yasuhiko Sakata, et al.
Circulation Journal (2016) Vol. 80, Iss. 6, pp. 1396-1403
Open Access | Times Cited: 35
Emerging Therapies for the Management of Decompensated Heart Failure
Emil M. deGoma, Randall H. Vagelos, Michael B. Fowler, et al.
Journal of the American College of Cardiology (2006) Vol. 48, Iss. 12, pp. 2397-2409
Closed Access | Times Cited: 50
Emil M. deGoma, Randall H. Vagelos, Michael B. Fowler, et al.
Journal of the American College of Cardiology (2006) Vol. 48, Iss. 12, pp. 2397-2409
Closed Access | Times Cited: 50
EVEREST study: Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan
João L. Cavalcante, Sadiya S. Khan, Mihai Gheorghiade
Expert Review of Cardiovascular Therapy (2008) Vol. 6, Iss. 10, pp. 1331-1338
Closed Access | Times Cited: 44
João L. Cavalcante, Sadiya S. Khan, Mihai Gheorghiade
Expert Review of Cardiovascular Therapy (2008) Vol. 6, Iss. 10, pp. 1331-1338
Closed Access | Times Cited: 44
Tolvaptan for the treatment of heart failure: a review of the literature
Andrew P. Ambrosy, Steven R. Goldsmith, Mihai Gheorghiade
Expert Opinion on Pharmacotherapy (2011) Vol. 12, Iss. 6, pp. 961-976
Closed Access | Times Cited: 39
Andrew P. Ambrosy, Steven R. Goldsmith, Mihai Gheorghiade
Expert Opinion on Pharmacotherapy (2011) Vol. 12, Iss. 6, pp. 961-976
Closed Access | Times Cited: 39
Congestion as a Therapeutic Target in Acute Heart Failure Syndromes
Steven R. Goldsmith, F Brandimarte, Mihai Gheorghiade
Progress in Cardiovascular Diseases (2010) Vol. 52, Iss. 5, pp. 383-392
Closed Access | Times Cited: 38
Steven R. Goldsmith, F Brandimarte, Mihai Gheorghiade
Progress in Cardiovascular Diseases (2010) Vol. 52, Iss. 5, pp. 383-392
Closed Access | Times Cited: 38
Effects of Tolvaptan on Volume Overload in Japanese Patients with Heart Failure: Results of a Phase II, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study
Masunori Matsuzaki, Masatsugu Hori, Tohru Izumi, et al.
Cardiovascular Drugs and Therapy (2011) Vol. 25, Iss. S1, pp. 19-31
Closed Access | Times Cited: 37
Masunori Matsuzaki, Masatsugu Hori, Tohru Izumi, et al.
Cardiovascular Drugs and Therapy (2011) Vol. 25, Iss. S1, pp. 19-31
Closed Access | Times Cited: 37
Tolvaptan Increases Serum Sodium in Pediatric Patients With Heart Failure
Rebecca B. Regen, Ashley Gonzalez, Kasey Zawodniak, et al.
Pediatric Cardiology (2013) Vol. 34, Iss. 6, pp. 1463-1468
Closed Access | Times Cited: 34
Rebecca B. Regen, Ashley Gonzalez, Kasey Zawodniak, et al.
Pediatric Cardiology (2013) Vol. 34, Iss. 6, pp. 1463-1468
Closed Access | Times Cited: 34
Safety and efficacy of long-term tolvaptan therapy for decompensated liver cirrhosis
Tomomi Kogiso, Katsutoshi Tokushige, Etsuko Hashimoto, et al.
Hepatology Research (2015) Vol. 46, Iss. 3
Open Access | Times Cited: 33
Tomomi Kogiso, Katsutoshi Tokushige, Etsuko Hashimoto, et al.
Hepatology Research (2015) Vol. 46, Iss. 3
Open Access | Times Cited: 33
Predictive parameter of tolvaptan effectiveness in cirrhotic ascites
Hideto Kawaratani, Hiroshi Fukui, Kei Moriya, et al.
Hepatology Research (2016) Vol. 47, Iss. 9, pp. 854-861
Closed Access | Times Cited: 31
Hideto Kawaratani, Hiroshi Fukui, Kei Moriya, et al.
Hepatology Research (2016) Vol. 47, Iss. 9, pp. 854-861
Closed Access | Times Cited: 31
Tolvaptan in Patients Hospitalized With Acute Heart Failure
G. Michael Felker, Robert J. Mentz, Kirkwood F. Adams, et al.
Circulation Heart Failure (2015) Vol. 8, Iss. 5, pp. 997-1005
Open Access | Times Cited: 30
G. Michael Felker, Robert J. Mentz, Kirkwood F. Adams, et al.
Circulation Heart Failure (2015) Vol. 8, Iss. 5, pp. 997-1005
Open Access | Times Cited: 30
